LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 76

Search options

  1. Article ; Online: Vaccination of Pregnant Women Against COVID-19.

    Abu-Raya, Bahaa

    NeoReviews

    2021  Volume 22, Issue 9, Page(s) e570–e573

    Abstract: Pregnant women are at increased risk for severe morbidity and mortality following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leading some countries to recommend vaccination of pregnant women against coronavirus disease ... ...

    Abstract Pregnant women are at increased risk for severe morbidity and mortality following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leading some countries to recommend vaccination of pregnant women against coronavirus disease 2019 (COVID-19). These recommendations are based on studies conducted early in the pandemic, and thus, the pregnant women in these studies most likely did not have pre-existing immunity to SARS-CoV-2 at the time of infection. The susceptibility of pregnant women and their infants to SARS-CoV-2 and the severity of infection may be attenuated as the pandemic progresses and an increasing number of women will have pre-existing immunity (following natural infection or vaccination prior to pregnancy) during pregnancy. The reactogenicity, immunogenicity and efficacy of COVID-19 vaccines administered in pregnancy may also be affected by the pre-existing immunity of pregnant women. Maternal vaccine trials should be evaluated in the context of their timing in the pandemic and interpreted based on the pre-existing immunity of pregnant women.
    MeSH term(s) COVID-19/immunology ; COVID-19/mortality ; COVID-19/prevention & control ; COVID-19/virology ; COVID-19 Vaccines/administration & dosage ; COVID-19 Vaccines/adverse effects ; COVID-19 Vaccines/immunology ; Female ; Humans ; Pregnancy ; Pregnancy Complications, Infectious/immunology ; Pregnancy Complications, Infectious/mortality ; Pregnancy Complications, Infectious/prevention & control ; Pregnancy Complications, Infectious/virology ; Pregnant Women ; SARS-CoV-2/immunology ; Vaccination
    Chemical Substances COVID-19 Vaccines
    Language English
    Publishing date 2021-09-08
    Publishing country United States
    Document type Journal Article
    ISSN 1526-9906
    ISSN (online) 1526-9906
    DOI 10.1542/neo.22-9-e570
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Predictors of Refractory Coronavirus Disease (COVID-19) Pneumonia.

    Abu-Raya, Bahaa

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2020  Volume 71, Issue 15, Page(s) 895–896

    MeSH term(s) Betacoronavirus/pathogenicity ; COVID-19 ; Coronavirus Infections/diagnosis ; Coronavirus Infections/epidemiology ; Coronavirus Infections/virology ; Humans ; Pandemics ; Pneumonia/diagnosis ; Pneumonia/epidemiology ; Pneumonia/virology ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/virology ; SARS-CoV-2
    Keywords covid19
    Language English
    Publishing date 2020-04-09
    Publishing country United States
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciaa409
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Extending Timing of Immunization Against Pertussis During Pregnancy and Protection of Premature Infants From Whooping Cough Disease.

    Abu-Raya, Bahaa

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2020  Volume 73, Issue 9, Page(s) e2509–e2511

    MeSH term(s) Female ; Humans ; Immunization ; Infant ; Infant, Newborn ; Infant, Premature ; Pregnancy ; Vaccination ; Whooping Cough/prevention & control
    Language English
    Publishing date 2020-06-19
    Publishing country United States
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciaa831
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Protection of the Newborn Through Vaccination in Pregnancy.

    Abu-Raya, Bahaa / Maertens, Kirsten

    NeoReviews

    2020  Volume 22, Issue 1, Page(s) e25–e39

    Abstract: Newborns and infants are at risk for severe infections with some pathogens (eg, ...

    Abstract Newborns and infants are at risk for severe infections with some pathogens (eg,
    MeSH term(s) Female ; Humans ; Infant, Newborn ; Pregnancy ; Vaccination ; Vaccine-Preventable Diseases/prevention & control
    Language English
    Publishing date 2020-12-09
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ISSN 1526-9906
    ISSN (online) 1526-9906
    DOI 10.1542/neo.22-1-e25
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Correlates of Protection Against Respiratory Syncytial Virus Infection in Infancy.

    Abu-Raya, Bahaa / Reicherz, Frederic / Lavoie, Pascal M

    Clinical reviews in allergy & immunology

    2022  Volume 63, Issue 3, Page(s) 371–380

    Abstract: The highest morbidity and mortality from respiratory syncytial virus (RSV) infection occurs in young infants. Immunization of expectant mothers during pregnancy has the potential to substantially reduce the burden of RSV disease in a majority of infants. ...

    Abstract The highest morbidity and mortality from respiratory syncytial virus (RSV) infection occurs in young infants. Immunization of expectant mothers during pregnancy has the potential to substantially reduce the burden of RSV disease in a majority of infants. Correlates of protection (COP) are important in guiding the development of maternal RSV vaccines and the design of maternal RSV vaccine trials, as immune response to candidate vaccines should mirror protective RSV immunity at birth. Here, we review the literature reporting correlations between RSV immune measures at birth and clinical RSV outcomes during infancy. Less than a dozen studies have investigated immunological COP with RSV disease or related hospitalization, yielding inconsistent findings overall. The differences in findings between studies could be due to differences in inclusion/exclusion criteria (e.g., the inclusion of older infants who may benefit less from maternal antibodies or infants followed during inter-seasonal periods where RSV is absent), differences in semi-quantitative RSV antibody neutralization assays, or differences in RSV outcome measures such as the sensititivity/specificity of diagnostic tests. Future research in this field should seek to standardize RSV immunological measures and outcomes, expand the breadth of functional RSV measures beyond antibody neutralization, and consider infants' age and seasonality of RSV infection.
    MeSH term(s) Infant ; Infant, Newborn ; Pregnancy ; Female ; Animals ; Humans ; Respiratory Syncytial Virus Infections/epidemiology ; Respiratory Syncytial Virus Infections/prevention & control ; Antibodies, Viral ; Sigmodontinae ; Respiratory Syncytial Virus Vaccines ; Respiratory Syncytial Viruses ; Respiratory Syncytial Virus, Human
    Chemical Substances Antibodies, Viral ; Respiratory Syncytial Virus Vaccines
    Language English
    Publishing date 2022-06-11
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1239045-8
    ISSN 1559-0267 ; 1080-0549
    ISSN (online) 1559-0267
    ISSN 1080-0549
    DOI 10.1007/s12016-022-08948-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Predictors of Refractory Coronavirus Disease (COVID-19) Pneumonia

    Abu-Raya, Bahaa

    Clinical Infectious Diseases

    2020  Volume 71, Issue 15, Page(s) 895–896

    Keywords Microbiology (medical) ; Infectious Diseases ; covid19
    Language English
    Publisher Oxford University Press (OUP)
    Publishing country uk
    Document type Article ; Online
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciaa409
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Article ; Online: A Novel Anti-nucleocapsid Antibody Avidity Method for Identifying SARS-CoV-2 Reinfections.

    Golding, Liam / Watts, Allison W / Shew, Jacob / Viñeta Paramo, Marina / Mâsse, Louise C / Goldfarb, David M / Abu-Raya, Bahaa / Lavoie, Pascal M

    The Journal of infectious diseases

    2024  

    Abstract: Detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfections is challenging with current serology assays and is further complicated by the marked decrease in routine viral testing practices as viral transmission increased during ... ...

    Abstract Detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfections is challenging with current serology assays and is further complicated by the marked decrease in routine viral testing practices as viral transmission increased during Omicron. Here, we provide proof-of-principle that high-avidity anti-nucleocapsid (N) antibodies detects reinfections after a single infection with higher specificity (85%; 95% confidence interval [95% CI], 80%-90%) compared to anti-N antibody levels (72%; 95% CI, 66%-79%) in a vaccinated cohort. This method could be used to retroactively investigate the epidemiology and incremental long-term health consequences of SARS-CoV-2 reinfections.
    Language English
    Publishing date 2024-03-05
    Publishing country United States
    Document type Journal Article
    ZDB-ID 3019-3
    ISSN 1537-6613 ; 0022-1899
    ISSN (online) 1537-6613
    ISSN 0022-1899
    DOI 10.1093/infdis/jiae072
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Why has the epidemiology of RSV changed during the COVID-19 pandemic?

    Abu-Raya, Bahaa / Viñeta Paramo, Marina / Reicherz, Frederic / Lavoie, Pascal Michel

    EClinicalMedicine

    2023  Volume 61, Page(s) 102089

    Abstract: The coronavirus disease 2019 (COVID-19) pandemic has drastically perturbed the epidemiology of Respiratory Syncytial Virus (RSV) respiratory tract infections in children. The reasons for this are not clear. In this article, we review the current ... ...

    Abstract The coronavirus disease 2019 (COVID-19) pandemic has drastically perturbed the epidemiology of Respiratory Syncytial Virus (RSV) respiratory tract infections in children. The reasons for this are not clear. In this article, we review the current literature and critically discuss the different theories to explain why the epidemiology of RSV has changed during the COVID-19 pandemic. Proposed mechanisms include decreased viral immunity in vulnerable age groups caused by the prolonged lack of RSV circulation early in the pandemic, potential Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2)-induced immune dysregulation, viral interactions between SARS-CoV-2 and RSV, and modifications in health-seeking behaviors as well as heath systems factors. Research in viral genomics and phylogeny, and more robust immunology research is needed to guide RSV prevention and health care resource planning.
    Language English
    Publishing date 2023-07-06
    Publishing country England
    Document type Journal Article ; Review
    ISSN 2589-5370
    ISSN (online) 2589-5370
    DOI 10.1016/j.eclinm.2023.102089
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Efficacy of Palivizumab Immunoprophylaxis for Reducing Severe RSV Outcomes in Children with Immunodeficiencies: A Systematic Review.

    Reicherz, Frederic / Abu-Raya, Bahaa / Akinseye, Omolabake / Rassekh, Shahrad Rod / Wiens, Matthew O / Lavoie, Pascal M

    Journal of the Pediatric Infectious Diseases Society

    2024  Volume 13, Issue 2, Page(s) 136–143

    Abstract: Background: Palivizumab is recommended for prevention of severe respiratory syncytial virus (RSV) disease in immunocompromised children, despite a lack of strong supporting evidence. The recent approval of substitute RSV-neutralizing monoclonal ... ...

    Abstract Background: Palivizumab is recommended for prevention of severe respiratory syncytial virus (RSV) disease in immunocompromised children, despite a lack of strong supporting evidence. The recent approval of substitute RSV-neutralizing monoclonal antibodies against RSV, offers an opportunity to synthesize the most current evidence supporting the palivizumab standard of care.
    Objective: To evaluate the efficacy of palivizumab in preventing acute respiratory tract infection- or RSV-related hospitalization, or mortality in immunocompromised children.
    Methods: We searched Ovid MEDLINE and EMBASE for published clinical studies that investigated outcomes of palivizumab use in children. We included clinical trials, cohort studies, and case-control studies. The primary outcomes were RSV-related or respiratory viral infection-related hospitalizations, or RSV-related mortality. This systematic review was registered in PROSPERO (ID CRD42021248619) and is reported in accordance with the PRISMA guidelines.
    Results: From the 1993 records, six studies were eligible and included, for a total of 625 immunocompromised children with an heterogeneous composition of primary and acquired immunodeficiencies enrolled from palivizumab programs. There were no intervention studies. None of the studies included a control group. RSV hospitalizations were infrequent (0%-3.1% of children). Most children included received palivizumab, although one study (n = 56) did not specify how many received palivizumab. RSV mortality was neither observed, in three studies, nor reported, in three other studies.
    Conclusions: The evidence supporting the use of palivizumab for prevention of severe RSV disease in immunocompromised children remains extremely limited and appears insufficient to justify prioritizing this intervention as the current standard of care over alternative interventions.
    MeSH term(s) Child ; Humans ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antiviral Agents/therapeutic use ; Hospitalization ; Immunologic Deficiency Syndromes/complications ; Palivizumab/therapeutic use ; Respiratory Syncytial Virus Infections/drug therapy ; Respiratory Syncytial Virus Infections/prevention & control ; Respiratory Syncytial Viruses
    Chemical Substances Antibodies, Monoclonal, Humanized ; Antiviral Agents ; Palivizumab (DQ448MW7KS)
    Language English
    Publishing date 2024-01-27
    Publishing country England
    Document type Systematic Review ; Journal Article
    ZDB-ID 2668791-4
    ISSN 2048-7207 ; 2048-7193
    ISSN (online) 2048-7207
    ISSN 2048-7193
    DOI 10.1093/jpids/piae004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top